| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 74.8 | ¤815,734 | US |
| JNJ | Johnson & Johnson | 65.6 | ¤455,044 | US |
| ABT | Abbott Laboratories | 59.4 | ¤214,959 | US |
| MRK | Merck & Co., Inc. | 67.2 | ¤214,759 | US |
| TMO | Thermo Fisher Scientific Inc. | 49.4 | ¤213,173 | US |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| DGX | Quest Diagnostics Incorporated | 52.8 | ¤19,573 | US |
| ZBH | Zimmer Biomet Holdings, Inc. | 53.4 | ¤19,921 | US |
| LH | Labcorp Holdings Inc. | 51.6 | ¤21,053 | US |
| PODD | Insulet Corporation | 61.5 | ¤22,034 | US |
| DXCM | DexCom, Inc. | 69.5 | ¤22,707 | US |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 61.9 | 31 | US |
| LLY | Eli Lilly and Company | 74.8 | 26 | US |
| PFE | Pfizer Inc. | 62.9 | 24 | US |
| DGX | Quest Diagnostics Incorporated | 52.8 | 22 | US |
| ZTS | Zoetis, Inc. Class A | 59.7 | 22 | US |
| BMY | Bristol-Myers Squibb Company | 57.5 | 21 | US |
| JNJ | Johnson & Johnson | 65.6 | 21 | US |
| TMO | Thermo Fisher Scientific Inc. | 49.4 | 21 | US |
| RMD | ResMed Inc. | 70.2 | 19 | US |
| GILD | Gilead Sciences, Inc. | 68.5 | 18 | US |
| Average Market Cap | ¤126,988 |
| Median Market Cap | ¤68,492 |
| Avg. 3 Mo. Dollar Vol. | ¤649,911,291 |
| Avg. 3 Mo. Trading Vol. | 5,207,840 |
| Last Rebalance Date | 09/22/2025 |
| Companies Replaced | 10 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 25.3 |
| Forward P/E Ratio (12 Mo.) | 17.6 |
| Price/Book Ratio | 5.7 |
| Avg. Revenue Chg. - 3 Yr | 11.1% |
| Avg. Op. Income Chg. - 3 Yr. | 19.8% |
| Avg. EPS Growth - 3 Yr. | 9.6% |
| Avg. EPS Growth - 1 Yr. | 11.5% |
| Avg. Operating Margin | 18.8% |
| Avg. LT Debt to Total Capital | 42.0% |
| Avg. Return on Equity | 19.6% |
| Dividend Yield | 0.9% |
| US Health Care Index | 59.67 |
| United States Of America | 90.0% |
| Ireland | 6.67% |
| Switzerland | 3.33% |
